PBPIA
FUSN

Pivotal bioVenture Partners Investment Advisor’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-563,385
Closed -$12M – 11
2024
Q1 		$12M Sell
563,385
-997,597
-64% -$11.9M 7.72% 5
2023
Q4 		$15M Hold
1,560,982
– – 3.81% 5
2023
Q3 		$4.06M Hold
1,560,982
– – 1.62% 7
2023
Q2 		$7.29M Hold
1,560,982
– – 2.4% 7
2023
Q1 		$5.88M Sell
1,560,982
-2
-0% -$8 2.42% 7
2022
Q4 		$4.92M Hold
1,560,984
– – 2.14% 6
2022
Q3 		$4.7M Buy
1,560,984
+2
+0% +$5 1.72% 9
2022
Q2 		$3.89M Sell
1,560,982
-37,395
-2% -$172K 1.96% 8
2022
Q1 		$12.4M Hold
1,598,377
– – 5.88% 4
2021
Q4 		$6.51M Sell
1,598,377
-2
-0% -$12 2.72% 10
2021
Q3 		$12.7M Buy
1,598,379
+2
+0% +$17 4.47% 9
2021
Q2 		$12.6M Sell
1,598,377
-2
-0% -$17 4.97% 8
2021
Q1 		$17.1M Hold
1,598,379
– – 5.5% 7
2020
Q4 		$18.8M Buy
+1,598,379
New +$20.1M 6.19% 7

Pivotal bioVenture Partners Investment Advisor's FUSN Position: Q2 2024 in Review

Pivotal bioVenture Partners Investment Advisor sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 563,385 shares — an estimated $12M sold.

Pivotal bioVenture Partners Investment Advisor first reported a position in FUSN in Q4 2020 and held it in 14 quarters. The position peaked at $18.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

  • Pivotal bioVenture Partners Investment Advisor reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
  • Pivotal bioVenture Partners Investment Advisor sold 563,385 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $12M.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2020 and held it in 14 quarters.
  • Pivotal bioVenture Partners Investment Advisor's Fusion Pharmaceuticals Inc. Common Shares position peaked at $18.8M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2024, filed 13 Aug 2024.